Cucarull, B.; Tutusaus, A.; SubÃas, M.; Stefanovic, M.; Hernáez-Alsina, T.; Boix, L.; Reig, M.; GarcÃa de Frutos, P.; MarÃ, M.; Colell, A.;
et al. Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models. Cancers 2020, 12, 332.
https://doi.org/10.3390/cancers12020332
AMA Style
Cucarull B, Tutusaus A, SubÃas M, Stefanovic M, Hernáez-Alsina T, Boix L, Reig M, GarcÃa de Frutos P, Marà M, Colell A,
et al. Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models. Cancers. 2020; 12(2):332.
https://doi.org/10.3390/cancers12020332
Chicago/Turabian Style
Cucarull, Blanca, Anna Tutusaus, Miguel SubÃas, Milica Stefanovic, Tania Hernáez-Alsina, Loreto Boix, MarÃa Reig, Pablo GarcÃa de Frutos, Montserrat MarÃ, Anna Colell,
and et al. 2020. "Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models" Cancers 12, no. 2: 332.
https://doi.org/10.3390/cancers12020332
APA Style
Cucarull, B., Tutusaus, A., SubÃas, M., Stefanovic, M., Hernáez-Alsina, T., Boix, L., Reig, M., GarcÃa de Frutos, P., MarÃ, M., Colell, A., Bruix, J., & Morales, A.
(2020). Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models. Cancers, 12(2), 332.
https://doi.org/10.3390/cancers12020332